Narrowing the knowledge gaps for melanoma

Upsala Journal of Medical Sciences

Volumn 117, Issue 2, 2012, Pages 237-243

  Slipicevic, Ana ^a,b   Herlyn, Meenhard ^a  

^a WISTAR INSTITUTE   (United States)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Molecular biology; Oncogenes; Tumor biology

Indexed keywords

ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; IPILIMUMAB; MONOCLONAL ANTIBODY; SULFONAMIDE; VEMURAFENIB;

HUMAN; MELANOMA; PATHOLOGY; REVIEW; SKIN TUMOR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; INDOLES; MELANOMA; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84859914846     PISSN: 03009734     EISSN: None     Source Type: Journal    
DOI: 10.3109/03009734.2012.658977     Document Type: Review

References (59)

1. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med. 2004;351:998-1012.
2. Monahan KB, Rozenberg GI, Krishnamurthy J, Johnson SM, Liu W, Bradford MK, et al. Somatic p16(INK4a) loss accelerates melanomagenesis. Oncogene. 2010;29:5809-17.
3. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135-47. (Pubitemid 41653105)
4. Meyle KD, Guldberg P. Genetic risk factors for melanoma. Hum Genet. 2009;126:499-510.
5. Flaherty KT, Fisher DE. New strategies in metastatic melanoma: oncogene-defined taxonomy leads to therapeutic advances. Clin Cancer Res. 2011;17:4922-8.
6. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-16.
7. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809-19.
8. Inamdar GS, Madhunapantula SV, Robertson GP. Targeting the MAPK pathway in melanoma: Why some approaches succeed and other fail. Biochem Pharmacol. 2010;80:624-37.
9. Villanueva J, Vultur A, Herlyn M. Resistance to BRAF Inhibitors: unraveling mechanisms and future treatment options. Cancer Res. 2011;71:7137-40.
10. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468:973-7.
11. Poulikakos PI, Rosen N. Mutant BRAF melanomas\-dependence and resistance. Cancer Cell. 2011;19:11-15.
12. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010;18:683-95.
13. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24:4340-6. (Pubitemid 46630793)
14. Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol. 2008; 26:2046-51.
15. Lutzky J, Bauer J, Bastian BC. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res. 2008;21: 492-3. (Pubitemid 351990966)
16. Box NF, Terzian T. The role of p53 in pigmentation, tanning and melanoma. Pigment Cell Melanoma Res. 2008;21: 525-33.
17. Easty DJ, Gray SG, O'Byrne KJ, O'Donnell D, Bennett DC. Receptor tyrosine kinases and their activation in melanoma. Pigment Cell Melanoma Res. 2011;24:446-61.
18. O'Connell MP, Weeraratna AT. Hear the Wnt Ror: how melanoma cells adjust to changes in Wnt. Pigment Cell Melanoma Res. 2009;22:724-39.
19. Strizzi L, Hardy KM, Kirsammer GT, Gerami P, Hendrix MJ. Embryonic signaling in melanoma: potential for diagnosis and therapy. Lab Invest. 2011;91:819-24.
20. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipili-mumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-23.
21. Ernfors P. Cellular origin and developmental mechanisms during the formation of skin melanocytes. Exp Cell Res. 2010;316:1397-407.
22. Haass NK, Herlyn M. Normal human melanocyte homeo-stasis as a paradigm for understanding melanoma. J Investig Dermatol Symp Proc. 2005;10:153-63.
23. Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, Delmas V, et al. Oncogenic Braf induces melano-cyte senescence and melanoma in mice. Cancer Cell. 2009;15: 294-303.
24. Patton EE, Widlund HR, Kutok JL, Kopani KR, Amatruda JF, Murphey RD, et al. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol. 2005;15:249-54. (Pubitemid 40205706)
25. Bansal R, Nikiforov MA. Pathways of oncogene-induced senescence in human melanocytic cells. Cell Cycle. 2010;9: 2782-8.
26. Cagnol S, Chambard JC. ERK and cell death: mechanisms of ERK-induced cell death\-apoptosis, autophagy and senescence. FEBS J. 2010;277:2-21.
27. Denoyelle C, Abou-Rjaily G, Bezrookove V, Verhaegen M, Johnson TM, Fullen DR, et al. Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol. 2006;8:1053-63. (Pubitemid 44473600)
28. Zhuang D, Mannava S, Grachtchouk V, Tang WH, Patil S, Wawrzyniak JA, et al. C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells. Oncogene. 2008;27:6623-34.
29. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33:19-20. (Pubitemid 36068675)
30. Haferkamp S, Tran SL, Becker TM, Scurr LL, Kefford RF, Rizos H. The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence. Aging (Albany NY). 2009;1:542-56.
31. Dumaz N, Hayward R, Martin J, Ogilvie L, Hedley D, Curtin JA, et al. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res. 2006;66:9483-91. (Pubitemid 44623646)
32. Pavey S, Johansson P, Packer L, Taylor J, Stark M, Pollock PM, et al. Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene. 2004; 23:4060-7. (Pubitemid 38747936)
33. MannavaS, Omilian AR, Wawrzyniak JA, Fink EE, Zhuang D, Miecznikowski JC, et al. PP2A-B56alpha controls oncogene-induced senescence in normal and tumor human melanocytic cells. Oncogene. 2011;Aug8 [Epub ahead of print].
34. Homig-Holzel C, van Doorn R, Vogel C, Germann M, Cecchini MG, Verdegaal E, et al. Antagonistic TSC22D1 variants control BRAF(E600)-induced senescence. EMBO J. 2011;30:1753-65.
35. Licciulli S, Luise C, Scafetta G, Capra M, Giardina G, Nuciforo P, et al. Pirin inhibits cellular senescence in mela-nocytic cells. Am J Pathol. 2011;178:2397-406.
36. Miyazaki I, Simizu S, Okumura H, Takagi S, Osada H. A small-molecule inhibitor shows that pirin regulates migration of melanoma cells. Nat Chem Biol. 2010;6:667-73.
37. Ha L, Ichikawa T, Anver M, Dickins R, Lowe S, Sharpless NE, et al. ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence. Proc Natl Acad Sci USA. 2007;104:10968-73. (Pubitemid 47175210)
38. Delmas V, Beermann F, Martinozzi S, Carreira S, Ackermann J, Kumasaka M, et al. Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev. 2007;21:2923-35. (Pubitemid 350133440)
39. Ackermann J, Beermann F. The fibroblast growth factor-2 is not essential for melanoma formation in a transgenic mouse model. Pigment Cell Res. 2005;18:315-19. (Pubitemid 41032891)
40. Chin L, Pomerantz J, Polsky D, Jacobson M, Cohen C, Cordon-Cardo C, et al. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev. 1997;11:2822-34. (Pubitemid 27481683)
41. Gupta PB, Kuperwasser C, Brunet JP, Ramaswamy S, Kuo WL, Gray JW, et al. The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet. 2005;37:1047-54. (Pubitemid 41486656)
42. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 2005;436:117-22. (Pubitemid 40966196)
43. Yu H, McDaid R, Lee J, Possik P, Li L, Kumar SM, et al. The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes. Am J Pathol. 2009;174:2367-77.
44. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE Jr, et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet. 2009;41:544-52.
45. Chudnovsky Y, Adams AE, Robbins PB, Lin Q, Khavari PA. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nat Genet. 2005;37:745-9. (Pubitemid 41754892)
46. Lo RS, Witte ON. Transforming growth factor-beta activation promotes genetic context-dependent invasion of immortalized melanocytes. Cancer Res. 2008;68:4248-57.
47. Schouwey K, Beermann F. The Notch pathway: hair graying and pigment cell homeostasis. Histol Histopathol. 2008;23: 609-19. (Pubitemid 351552347)
48. Pinnix CC, Lee JT, Liu ZJ, McDaid R, Balint K, Beverly LJ, et al. Active Notch1 confers a transformed pheno-type to primary human melanocytes. Cancer Res. 2009;69: 5312-20.
49. Amos CI, Wang LE, Lee JE, Gershenwald JE, Chen WV, Fang S, et al. Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Hum Mol Genet. 2011;20:5012-23.
50. Barrett JH, Iles MM, Harland M, Taylor JC, Aitken JF, Andresen PA, et al. Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet. 2011;43: 1108-13.
51. Nan H, Qureshi AA, Prescott J, De Vivo I, Han J. Genetic variants in telomere-maintaining genes and skin cancer risk. Hum Genet. 2011;129:247-53.
52. Bataille V, Kato BS, Falchi M, Gardner J, Kimura M, Lens M, et al. Nevus size and number are associated with telomere length and represent potential markers of a decreased senescence in vivo. Cancer Epidemiol Biomarkers Prev. 2007; 16:1499-502. (Pubitemid 47076885)
53. Han J, Qureshi AA, Prescott J, Guo Q, Ye L, Hunter DJ, et al. A prospective study of telomere length and the risk of skin cancer. J Invest Dermatol. 2009;129:415-21.
54. Soo JK, Mackenzie Ross AD, Kallenberg DM, Milagre C, Heung Chong W, Chow J, et al. Malignancy without immortality? Cellular immortalization as a possible late event in melanoma progression. Pigment Cell Melanoma Res. 2011; 24:490-503.
55. Macgregor S, Montgomery GW, Liu JZ, Zhao ZZ, Henders AK, Stark M, et al. Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. Nat Genet. 2011;43:1114-18.
56. Ceol CJ, Houvras Y, Jane-Valbuena J, Bilodeau S, Orlando DA, Battisti V, et al. The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature. 2011;471:513-17.
57. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature. 2010;463:191-6.
58. Yang R, Jiang M, Kumar SM, Xu T, Wang F, Xiang L, et al. Generation of melanocytes from induced pluripotent stem cells. J Invest Dermatol. 2011;131:2458-66.
59. Nissan X, Larribere L, Saidani M, Hurbain I, Delevoye C, Feteira J, et al. Functional melanocytes derived from human pluripotent stem cells engraft into pluris-tratified epidermis. Proc Natl Acad Sci USA. 2011;108: 14861-6.